Business Wire

QUECTEL-WIRELESS

Share
Quectel IoT Modules Significantly More Secure Than Industry Average According to Finite State

Quectel Wireless Solutions, a global IoT solutions provider, today announces that, according to a recent milestone report by Finite State, an independent third-party cybersecurity firm, nearly 95% of all Quectel modules shipped to the United States since the beginning of 2022 have industry-leading security scores based on penetration testing and binary analysis by Finite State.

The report highlights a notable enhancement in Quectel's security position, expanding the number of modules tested and with scores across the tested modules improving from an average of 33 to 18, up from an average of 62 to 24 in previous testing. This represents a substantial improvement, as both the initial and revised scores significantly surpass the industry average of 98 with the lowest (best) score of 10. Further, the number of and severity of vulnerabilities Finite State did identify in Quectel products or modules are significantly less than the industry standard and revealed a very limited attack surface. Those issues Finite State did discover have been quickly remedied by Quectel.

This advanced phase of testing leverages Finite State's security technologies and expertise to conduct an exhaustive third-party evaluation of Quectel's modules. The advanced testing encompasses an array of sophisticated security assessments designed to fortify Quectel's modules against the evolving landscape of cyber threats, including binary analysis of numerous Quectel products and both penetration testing and binary analysis of several Quectel cellular modules.

"Entering this next phase of security testing with Finite State underscores our relentless pursuit of the highest security standards for our products," stated Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our continued collaboration is a reflection of our commitment to exceed industry security expectations, ensuring our customers benefit from the most secure and reliable communication modules available – tested and verified by one of the most trusted US cyber security firms. We’re thrilled that the latest report from Finite State demonstrates our commitment and progress."

The continued integration of Finite State into Quectel’s transparency and security program reaffirms Quectel’s commitment to pioneering unparalleled security practices in the IoT and telecommunications sectors. Quectel has made a measurable improvement in key areas such as the security health of the code, the sophistication of the vulnerability management process, and the transparency of its software supply chain.

The program is strategically designed with three key goals to address the pressing issues in cybersecurity today:

  1. Implementing the Finite State Platform into Quectel's DevSecOps procedures, which enhances firmware binary analysis, manages vulnerabilities efficiently, and offers specific recommendations for remediation.
  2. Developing and sharing Software Bill of Materials (SBOM) and Vulnerability Exploitability Exchange (VEX) documents for each of Quectel's products, which promotes a transparent environment and provides critical insights into the software components of Quectel's devices along with any vulnerabilities they may contain.
  3. Conducting comprehensive manual penetration tests by Finite State's expert Red Team, which augments automated testing methods and delivers detailed security evaluations for Quectel's product line.

Matt Wyckhouse, CEO of Finite State, commented, "Progressing to this next phase of security testing demonstrates Quectel’s commitment to leading the industry with transparent, rigorous cybersecurity practices. Quectel's willingness to subject their products to such rigorous scrutiny is commendable and sets a new industry standard to further safeguard the IoT ecosystem."

The outcome of this continued engagement is anticipated to enhance the security framework of Quectel's modules and inspire a shift towards more rigorous security standards across the telecommunications industry. Quectel is dedicated to sharing insights and best practices gleaned from this process, contributing to a safer, more secure digital future.

In addition to the activity with Finite State, Quectel is actively pursuing collaboration with multiple standards-setting organizations to enhance and commit to a more rigorous set of security requirements. This initiative aims to achieve key security certifications from both industry and governmental bodies, underlining Quectel's dedication to advancing security standards within the sector.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318703729/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye